The Solid Microneedle Drug Delivery System segmentation by application is typically divided into four principal categories: vaccination, cosmetic treatment, chronic disease management, and other niche uses. Vaccination accounts for the largest share, driven by the need for painless, thermostable delivery of prophylactic antigens, which expands the overall market size through large‑volume public‑health programs. Cosmetic applications, such as transdermal delivery of anti‑aging peptides and dermal fillers, contribute a substantial mid‑range portion, reflecting high consumer spending in aesthetic dermatology. Chronic disease management—encompassing insulin, peptide hormones, and biologics for conditions like rheumatoid arthritis—adds a steady revenue stream due to repeat dosing and long‑term therapy contracts. The residual “other” segment captures emerging uses (e.g., gene‑editing agents, veterinary vaccines) and represents a smaller but strategically important growth frontier. Each application’s market weight directly influences manufacturing capacity, R&D allocation, and regulatory focus, collectively shaping the total addressable market for solid microneedle platforms.